Laub PB - Search Results

1

Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies.

Salazar H, Godwin AK, Daly MB, Laub PB, Hogan WM, Rosenblum N, Boente MP, Lynch HT, Hamilton TC. Salazar H, et al. Among authors: laub pb. J Natl Cancer Inst. 1996 Dec 18;88(24):1810-20. doi: 10.1093/jnci/88.24.1810. J Natl Cancer Inst. 1996. PMID: 8961970

2

Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.

Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC. Johnson SW, et al. Among authors: laub pb. Cancer Res. 1997 Mar 1;57(5):850-6. Cancer Res. 1997. PMID: 9041185

3

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells.

Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP, Hamilton TC, O'Dwyer PJ, Johnson SW. Roberts D, et al. Among authors: laub pb. Br J Cancer. 2005 Mar 28;92(6):1149-58. doi: 10.1038/sj.bjc.6602447. Br J Cancer. 2005. PMID: 15726096 Free PMC article.

4

Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.

Gallo JM, Brennan J, Hamilton TC, Halbherr T, Laub PB, Ozols RF, O'Dwyer PJ. Gallo JM, et al. Among authors: laub pb. Cancer Res. 1995 Oct 15;55(20):4507-11. Cancer Res. 1995. PMID: 7553617 Clinical Trial.

5

Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose.

O'Dwyer PJ, Szarka C, Brennan JM, Laub PB, Gallo JM. O'Dwyer PJ, et al. Among authors: laub pb. Clin Cancer Res. 2000 Dec;6(12):4692-6. Clin Cancer Res. 2000. PMID: 11156221 Clinical Trial.

6

Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion.

O'Dwyer PJ, Laub PB, DeMaria D, Qian M, Reilly D, Giantonio B, Johnston AL, Wu EY, Bauman L, Clendeninn NJ, Gallo JM. O'Dwyer PJ, et al. Among authors: laub pb. Clin Cancer Res. 1996 Oct;2(10):1685-92. Clin Cancer Res. 1996. PMID: 9816117 Clinical Trial.

7

NCOMP--a windows-based computer program for noncompartmental analysis of pharmacokinetic data.

Laub PB, Gallo JM. Laub PB, et al. J Pharm Sci. 1996 Apr;85(4):393-5. doi: 10.1021/js9503744. J Pharm Sci. 1996. PMID: 8901075

8

Population pharmacokinetic model for topotecan derived from phase I clinical trials.

Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD. Gallo JM, et al. Among authors: laub pb. J Clin Oncol. 2000 Jun;18(12):2459-67. doi: 10.1200/JCO.2000.18.12.2459. J Clin Oncol. 2000. PMID: 10856106

9

Localized solution structure refinement of an F45W variant of ubiquitin using stochastic boundary molecular dynamics and NMR distance restraints.

Laub PB, Khorasanizadeh S, Roder H. Laub PB, et al. Protein Sci. 1995 May;4(5):973-82. doi: 10.1002/pro.5560040517. Protein Sci. 1995. PMID: 7663353 Free PMC article.

10

A noncovalent peptide complex as a model for an early folding intermediate of cytochrome c.

Wu LC, Laub PB, Elöve GA, Carey J, Roder H. Wu LC, et al. Among authors: laub pb. Biochemistry. 1993 Sep 28;32(38):10271-6. doi: 10.1021/bi00089a050. Biochemistry. 1993. PMID: 8399155

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters